Pain

Approximately 1 in 4 women with chronic pelvic pain (CPP) report persistent pelvic pain after hysterectomy. Centralized symptoms-fatigue, multisite pain, and sleep disturbance, quantified using the Fibromyalgia Survey Score (FSS)-often co-occur with this risk, but the trajectory of centralized symptom burden after surgery, independent of pelvic pain outcome, is not well understood. Whether presurgical differences in central nervous system pain processing distinguish women whose centralized symptoms improve (improvers) from those whose do not (non-improvers) has not been tested. In this observational study, we assessed whether individuals who do and do not report improvement in FSS scores six months post-operatively differ in their baseline/pre-operative phenotypes and brain function. Sensory sensitivity scores were significantly higher in non-improvers than in improvers at baseline. We identified no significant, presurgical differences in age, average pelvic pain intensity, widespread pain, or pain interference between improvers and non-improvers. Functional connectivity was examined at rest and during the application of a distal, sustained pressure pain. We identified no significant group differences at rest. During sustained pressure pain, non-improvers showed greater connectivity than improvers between primary somatosensory cortex and posterior thalamic seeds with frontal, motor, cerebellar and limbic regions, but lower connectivity between the periaqueductal gray and subgenual cingulate cortex. Non-improvers also showed a greater pain-evoked increase in connectivity between the pelvic and leg representations of the primary sensory cortex and other sensorimotor regions in the pain-versus-rest contrast. Overall, non-improvers showed increased functional connectivity between regions associated with the multisensory integration of ascending pain, and decreased connectivity between regions associated with descending pain modulation. In exploratory analyses, some of these connections were additionally associated with symptom burden: sensory sensitivity, number of painful regions, and pain interference. This work may inform mechanisms of persistent symptom burden and guide surgical decision-making in patients with high central sensitization.

Endometriosis is a common yet understudied condition in which sex hormones play a key role in the etiology and pathophysiology of the disease. Sex hormones are dysregulated in endometriosis and are pharmacologically targeted to reduce symptoms including pain, but the relationships between endometriosis-related pain with sex hormone levels and their receptors are not clear. In 60 women previously diagnosed or undergoing laparoscopic surgery for the diagnosis of endometriosis, we collected patient-reported endometriosis/pelvic pain intensity in the last 30 days, pain interference scale, and the Endometriosis Health Profile 30 (EHP30) pain subscale. In a sub-sample of 38 participants, biopsies from control non-lesion pelvic peritoneum and endometrial lesion tissues were collected during surgery to analyze the tissue abundance of the primary receptors for estrogen, as well as androgen, progesterone, and prolactin receptors. Serum was collected to analyze systemic sex hormone levels including estradiol, prolactin, progesterone, and testosterone. Between tissues, we found elevated transcript levels for estrogen receptor alpha (ESR1) in lesions, but no difference in estrogen receptor beta (ESR2) transcript levels between tissue samples were found. Relating tissue receptor transcript levels to clinical pain revealed that only ESR1 and PGR in lesions were negatively associated with endometriosis/pelvic pain intensity, however, following false discovery rate correction the association with ESR1 was no longer statistically significant. No other tissue or systemic factors were associated with clinical pain outcomes. Together, these data demonstrate unique alterations in receptor abundance in lesions yet select transcript levels only weakly relate to pain in endometriosis.

Multimodal hypersensitivity (MMH), heightened sensitivity across multiple sensory modalities, is associated with chronic pain risk in adults. How MMH develops across adolescence and whether early pain experiences shape its trajectory remains unknown. The Early Menstrual Pain Impact on Multisensory Hypersensitivity (EMPATHY) study followed 300 premenarcheal adolescents (age M=11.29, SD=0.98 years) across the menarcheal transition with three visits comprising a comprehensive multimodal sensory testing battery: visual and auditory unpleasantness, a non-invasive bladder filling task, pressure pain thresholds, after-pain ratings, cold pain, and conditioned pain modulation. A principal component (PC) analysis of 24 baseline measures (n=214) identified three components accounting for 34.2% of variance: MMH (PC1; 16.5% of variance), a pressure-pain stimulus-response function (PC2; 9.3%), and bladder hypersensitivity (PC3; 8.4%). All experimental measures, and four self-report sensory sensitivity questionnaires projected as supplementary variables, loaded onto PC1, supporting its interpretation as MMH and replicating the component structure previously observed in adult women. Longitudinal trajectories of MMH (n=140) were modeled with linear mixed-effects regression with menstrual pain, pelvic pain, time, and their interactions as predictors, adjusting for pubertal staging. MMH decreased across the menarcheal transition (p=0.029). Pelvic pain (p=1.24x10-6), but not menstrual pain (p=0.205), was positively associated with MMH, independent of time and pubertal development. These findings establish MMH as a measurable, replicable sensory phenotype in early adolescence that covaries with non-menstrual pelvic pain, and position it as a candidate early marker of nociplastic pain risk. Future studies are needed to support interventions and screening for elevated sensory sensitivity before pain becomes clinically entrenched.

Chronic pain in later life may be accompanied by alterations in brain structure and cognition, but whether pain extent and central sensitization symptoms identify distinct brain-behavior patterns remains unclear. We examined associations of pain extent and central sensitization symptoms, assessed using the 9-item Central Sensitization Inventory (CSI-9), with regional gray matter volume and cognitive function in community-dwelling older adults. This cross-sectional study included 272 participants with chronic pain from the Bunkyo Health Study. Participants were classified as having single-site or multisite pain and by CSI-9 score as having lower or higher scores, with 12 or higher defining the higher group. Regional gray matter volume was quantified using 0.3-Tesla magnetic resonance imaging, and cognition was assessed using the Trail Making Test Part B (TMT-B), processing speed, and global and domain-specific measures. Pain extent and CSI-9 group interacted for TMT-B performance, with the longest completion time in participants with single-site pain and a higher CSI-9 score. No other cognitive outcome remained significant after correction for multiple testing. In categorical analyses, the higher CSI-9 group had smaller volumes in the right middle frontal gyrus, bilateral anterior cingulate cortex, right insula, right hippocampus, and bilateral amygdala, whereas pain extent and the interaction were not associated with regional volume. In a contextual comparison, only the single-site/higher CSI-9 group showed slower TMT-B performance than participants with no current pain. Pain extent and central sensitization symptoms may represent partly distinct dimensions of chronic pain, although the small single-site/higher CSI-9 group and attenuation in several sensitivity analyses warrant caution. Significance StatementChronic pain is often described by where it hurts, but location alone may miss important differences between patients. In older adults, pain extent and symptoms measured by the 9-item Central Sensitization Inventory captured partly different aspects of chronic pain. Participants with pain at one site and a higher CSI-9 score performed most slowly on a task requiring attention and mental flexibility, whereas differences in regional brain structure were related mainly to CSI-9 score rather than pain extent. These findings support a multidimensional approach to chronic pain and may inform future research on cognitive vulnerability and brain health across pain conditions. Graphical Abstract Text O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=120 SRC="FIGDIR/small/742487v1_ufig1.gif" ALT="Figure 1"> View larger version (47K): org.highwire.dtl.DTLVardef@17eacb7org.highwire.dtl.DTLVardef@17d535borg.highwire.dtl.DTLVardef@ebb79forg.highwire.dtl.DTLVardef@16464b7_HPS_FORMAT_FIGEXP M_FIG C_FIG Among older adults with chronic pain, pain extent and CSI-9 score captured different aspects of vulnerability. Slower performance on a task requiring attention and cognitive flexibility was concentrated in those with single-site pain and higher CSI-9 scores, whereas regional brain-volume differences tracked CSI-9 category more broadly.

The Acute to Chronic Pain Signatures (A2CPS) project is a large, multisite, longitudinal observational study designed to identify biomarkers that predict the transition from acute to chronic pain following surgery in more than 2200 patients. Two participant cohorts were recruited before undergoing either knee arthroplasty or thoracic surgery. A unique feature of this study is its comprehensive evaluation of pain, including evoked and recall pain measures collected at baseline, 6-weeks, and 3-months following surgery, in addition to the primary pain outcome assessed remotely at 6 months. This paper describes the acquisition, quality control procedures, and available pain and pain sensitivity variables included in the A2CPS study. Self-report pain assessments include surgical site (i.e., index) pain intensity, pain interference and quality, spatial distribution of pain using body maps, and pain-related dysfunction specific to each cohort. Quantitative sensory testing yielded evoked pain sensitivity data including pressure pain thresholds, temporal summation of pain, dynamic mechanical allodynia, and conditioned pain modulation at both index and common sites across cohorts. Movement-evoked pain was assessed for each cohort using relevant functional tasks (knee: 10m walk and five-time-sit-to-stand tests, thoracic: deep breathing and coughing). Using baseline data from release v2.1.0, comprising approximately 1,400 participants, we evaluated interrelationships among pain variables. Overall, the A2CPS pain and pain sensitivity data provide a robust, comprehensive set of variables that supports the study goal of uncovering predictive biomarkers of post-operative chronic pain and enables broader exploration relative to other study outcomes, including imaging, psychosocial, and omics data.

Importance: Pain varies in its intensity and course, yet much of our understanding of pain is based on cross-sectional assessments or longitudinal studies of selected clinical populations. Routinely collected electronic health record data may enable characterization of longitudinal pain patterns at scale. Objective: To identify longitudinal pain profiles among U.S. Veterans and characterize their clinical and polygenic correlates. Design: Cohort study using electronic health record and genomic data from the Million Veteran Program, with up to 16 years of pain assessments collected between 2000 to 2025. Setting: U.S. Department of Veterans Affairs health care system. Participants: Million Veteran Program participants assigned to African-like, Admixed American-like, East Asian-like, European-like, or South Asian-like genetically inferred ancestry groups who have at least three years of outpatient numeric rating scale pain records. Exposures: Outpatient pain ratings and polygenic scores for psychiatric, sleep, and substance use traits. Main Outcomes and Measures: Pain profiles were identified using Gaussian finite mixture modeling of pain intensity, directional change, and within-person variability. Profiles were characterized by pain, psychiatric and substance use diagnoses, opioid exposure, body mass index, and polygenic scores. Results: Among 624,996 participants (Mean [SD] age at first pain rating=53.4 [13.5] years; 568,833 [91.0%] male), 51,731,567 outpatient pain ratings were analyzed. Three profiles were identified: stable no pain, stable mild pain, and mild-to-moderate increasing pain. Compared with the stable no pain profile, the increasing pain profile had higher odds of chronic pain (OR=21.14 [95% CI: 18.96-23.57]), opioid use disorder (OR=9.32 [95% CI: 8.31-10.45]), opioid exposure (OR=8.61 [95% CI: 8.41-8.83]), major depressive disorder (OR=3.77 [95% CI: 3.67-3.87]), and posttraumatic stress disorder (OR=3.72 [95% CI: 3.61-3.84]). Associations were attenuated but remained after adjustment for mean pain severity. Polygenic scores for depression, insomnia, attention-deficit/hyperactivity disorder, and tobacco use disorder were the most consistent predictors of increasing pain across the three largest genetically inferred ancestry groups. Conclusions and Relevance: Longitudinal modeling of routinely collected pain scores identified pain profiles associated with clinical burden and polygenic liability. These profiles captured clinically meaningful information beyond mean pain severity alone, highlighting the value of longitudinal pain phenotyping in electronic health record data.

Pain is associated with dynamic brain reorganization. Electroencephalographic microstates can characterize transient large-scale brain states, yet findings across pain studies are inconsistent. Two features may contribute: conditions have been studied in isolation, and analytical pipelines vary widely. We applied a harmonized analysis pipeline across three pain conditions: capsaicininduced pain, assessed within participants against a pain-free baseline, and non-chronic and chronic back pain, each compared with matched controls. Using a five-minute resting-state electroencephalographic recordings we examined microstate topography, temporal expression and transition probabilities, and directly compared pain related differences across pain states. We identified five microstates (A-E), corresponding to auditory, visual, salience, and attentional networks. Capsaicin pain showed increased expression of microstate C and reduced expression of microstates A, D and E. Transitions were redistributed towards microstate C, indicating a shift toward salience-related processing at the expense of sensory and attentional dynamics. In clinical back pain, effects were smaller and diverged by pain type: non-chronic back pain showed lower microstate C occurrence, opposite in direction to the capsaicin effect, whereas chronic back pain showed lower microstate D global explained variance, suggesting salience and attentional differences in clinical pain. Direct comparisons showed weaker pain-related increases in microstate C expression in both clinical back pain groups than capsaicin pain, with additional differences involving microstates A, D and E. These findings argue against a unitary EEG microstate signature of pain and instead reveal pain-type-specific patterns of large-scale brain dynamics, with microstate C providing the clearest distinction between experimental and clinical pain.

Urinary tract infections (UTIs) are a major risk factor for interstitial cystitis/bladder pain syndrome (IC/BPS), yet the mechanisms driving chronic pelvic pain and associated symptoms remain poorly understood. Here, we investigated the role of microglia and Toll-like receptor 4 (TLR4) in a mouse model of post-UTI chronic pelvic pain (PUPP). Infection with E. coli induced persistent pelvic allodynia that was significantly attenuated by microglial depletion (PLX5622) or inhibition (minocycline), indicating a key role for microglia in pain maintenance. In contrast, microglial depletion did not improve urinary dysfunction or anxiety- and depression-like behaviors. Prefrontal cortex microglia of PUPP mice exhibited reduced microglial branching complexity and a less ramified phenotype, indicative of an activated microglial state. Transcriptomic profiling of brain CD11b+ cells revealed a reactive microglial signature enriched for chemokines, NFKB-related genes, and immediate early response genes, alongside pathways involved in immune regulation and leukocyte recruitment. Both general and microglia-specific TLR4 deletion reduced pelvic allodynia and reduced microglial morphological features of activation. Consistent with this, pharmacological TLR4 inhibition in vitro suppressed LPS-induced NFKB activation, cytokine secretion, and CD68 expression. Together, these findings identify microglial TLR4 as a critical mediator of post-UTI chronic pelvic pain.

Endometriosis is a prevalent condition characterized by chronic pelvic pain that is frequently refractory to treatment. While the mechanisms underlying this pain remain poorly defined, clinical evidence often indicates that lesion innervation, but not disease stage (e.g. number and depth of lesions), correlate with pelvic pain severity. However, characterization of lesion-innervating neurons is incomplete, revealing an opportunity to identify novel, disease-modifying therapeutics. Here, we coupled functional analyses of lesion-innervating neurons in a mouse model with concurrent identification and characterization of lesion-innervating neurons from pain-phenotyped endometriosis patients. Following the confirmation of abdominal-directed pain-like behaviors in the mouse model, electrophysiological analysis revealed that lesion-innervating dorsal root ganglion (DRG) neurons are hyperexcitable compared to matched controls. These neurons are predominantly small-diameter and bind Isolectin B4, an established marker of the GDNF Family Ligand receptor, Ret. GDNF is concentrated within the stromal layer of both mouse and human lesions, adjacent to axons expressing the GDNF co-receptor, GFR1. Critically, clinical pain correlates with lesion GDNF level, axonal density, and neuronal GFR1 levels. These data provide evidence that endometrial lesions may recruit the Ret-positive subpopulation of nociceptors where they become sensitized and increase patient pain.

Chronic widespread pain (CWP) is highly prevalent among minoritized adults with clinical obesity, and symptom management is challenging. Weight loss via bariatric surgery is often recommended to improve musculoskeletal pain. However, there is significant variation in pain trajectories following bariatric surgery, and the impact of weight loss on movement-evoked pain is largely unknown. The current study aims to systematically characterize and quantify longitudinal changes in pain at rest and movement-evoked pain up to 6 months post-surgery, and to determine whether pain modulatory mechanisms, joint motion, and mechanical loading biosignatures mediate the relationship between weight loss and pain change. This study protocol details the research methodologies and procedures for a prospective observational cohort study of 60 individuals undergoing bariatric surgery for weight loss. Participants will complete questionnaires, anthropometric measurements, clinical and experimental pain testing, functional testing, and a standardized movement testing battery to assess joint motion and mechanical loading using camera-based motion capture before and at 3 and 6 months post-bariatric surgery. Generalized linear mixed models to assess the significance of changes in PAR, MEP, and all patient-reported outcome measures. Reduced models will treat the main effect of time as a fixed factor, and intra-individual repeated measures as random effects. Ethics and dissemination: This study protocol has been registered as an observational study with ClinicalTrials.gov (NCT0675386) in the United States and has been approved by the NYU Langone Health Institutional Review Board (IRB#: i21-01652) and the New York City Health + Hospitals/Bellevue Research Office (Bellevue Study ID #: STUDY00003739). Study results will be published in peer-reviewed journals and presented at national and international conferences and community events.

Background Adverse childhood experiences are associated with reduced healthy longevity, multimorbidity, and chronic pain, but the biological mechanisms involved remain poorly understood. Epigenetic age acceleration (EAA), a DNA methylation marker of biological aging, may represent a pathway through which early-life stress becomes embedded. We therefore examined associations between childhood trauma (CT), EAA and chronic pain, and investigated whether accelerated biological aging mediates the relationship between CT and chronic pain in women and men. Methods We analysed two independent population cohorts from the UK and USA: Generation Scotland (n = 901) and MIDUS (n = 1041). EAA was derived from first-generation (Hannum and Horvath) and second-generation (GrimAge and PhenoAge) DNA methylation clocks relative to chronological age. DunedinPACE, a third-generation measure, was used to estimate pace of aging. Associations between CT, EAA and chronic pain were examined using sex-stratified regression models adjusted for confounders and covariates, followed by mediation analyses. Findings CT was associated with chronic pain and with accelerated biological aging measured primarily using second- and third-generation clocks. Associations were consistently stronger in women, and smoking-related methylation contributed substantially to the relationship between EAA and chronic pain. Mediation analyses revealed that EAA partially accounts for the link between CT and chronic pain in women. Interpretation Second- and third-generation clocks appeared more sensitive to the long-term consequences of childhood trauma than clocks trained primarily on chronological age. The findings suggest that CT contributes to chronic pain vulnerability partly through accelerated biological aging pathways, particularly in women.

Background: Sleep, pain, affect, cognition and energy (SPACE) has been described as a latent symptom-severity construct in chronic overlapping pain conditions. Its population-level structure and associations with chronic pain interference and functional disability remain uncertain. Methods: We conducted a cross-sectional analysis of UK Biobank participants. Prespecified standardised symptom domains were examined using correlation analysis, principal component analysis, exploratory factor analysis and k-means clustering. Associations with chronic pain interference, current work disability, poor self-rated health and longstanding illness or disability were assessed using covariate-adjusted logistic regression. A four-domain score excluding pain tested whether associations extended beyond the pain domain. Secondary analyses examined convergence with actigraphy, biomarkers, polygenic risk scores and brain magnetic resonance imaging phenotypes. Results: Of 501,935 eligible participants, 475,134 had complete domain data. Domains were modestly intercorrelated (r=0.04-0.46). Clustering identified lower- and higher-burden phenotypes comprising 70.5% and 29.5% of participants; current work disability occurred in 1.3% and 10.3%, respectively. Adding the four non-pain domains increased the area under the curve for chronic pain interference from 0.593 to 0.672 and for work disability from 0.748 to 0.850. Inclusion of pain increased the work-disability area under the curve to 0.863. Multimodal measures added smaller increments. Conclusions: A multidimensional symptom profile was identifiable at population scale and was concurrently associated with chronic pain interference and work disability, with non-pain domains contributing information beyond pain burden alone.

Placebo analgesia varies substantially across individuals, yet the sources of this heterogeneity remain incompletely understood. Pain-reporting variability may represent an underrecognized predictor of placebo responsiveness. This study examined whether variability and reliability of pain reporting predict placebo analgesia in an experimental pain setting. Eight hundred and three participants (401 individuals with temporomandibular disorder and 400 healthy controls) completed a standardized thermal pain paradigm involving calibration, placebo conditioning, and testing phases. We obtained repeated heat temperatures (four) during thermal calibration and pain ratings during conditioning test (24 trials). We used these measurements to quantify within-person pain-reporting variability using standard deviation (SD) and coefficient of variation (CoV), and reliability using intraclass correlation coefficients (ICC). Placebo analgesia was calculated as the difference in pain ratings between control and placebo cue trials during testing. Regression models examined associations between reporter characteristics and placebo analgesia controlling for age, sex, race and experimenters. Variability of thermal pain responses during calibration did not predict placebo analgesia. Greater pain-reporting variability during conditioning was associated with reduced placebo analgesia (higher SD and CoV), and this effect was mediated by slower acquisition of the cue pain contingency. Conditioning-phase reliability was not associated with placebo analgesia, whereas three clusters of learning profiles predicted placebo effects. Thus, individual differences in pain-reporting variability during conditioning, rather than baseline sensory variability, contribute to heterogeneity in placebo analgesia. These findings suggest that variability during acquisition processing matters more than general sensory variability influencing the magnitude of placebo effects.

Despite urgent need for better analgesics, drug development has been complicated by incomplete bench-to-bedside translation. A likely contributing factor is the poor connection between the experimenter-evoked pain-related measures often used in preclinical models, and the clinical symptoms, like broader functional impairment, reported by patients. Here, we asked whether vertical climbing, a species-specific elective behaviour in mice, could serve as a measure of pain-related impairment. We tested male and female mice in a wide range of pain-related models including models of post-operative pain, inflammatory injury, osteoarthritis, rheumatoid arthritis, cancer-induced bone pain, fibrous dysplasia, neuropathic pain, migraine-related pain and facial neuropathy. Vertical climbing was reduced in all models, across five different laboratories, demonstrating the robustness and consistency of this type of behaviour as a novel pain-related outcome measure. Reduced climbing correlated significantly with established pain-related measures, but its time course diverged from that of evoked mechanical allodynia, while aligned more closely with other non-evoked behaviours, like burrowing, home cage activity, wheel running or weight bearing. Pharmacological validation was bidirectional: gabapentin restored climbing in mice with neuropathic injury, and naltrexone reinstated the climbing deficit in mice that had recovered from intraplantar CFA, consistent with persistent pain held in remission by endogenous opioid signalling. Overall, our results indicate that voluntary vertical climbing is a stable, elective behaviour that provides a robust and translationally relevant measure of pain-related functional impairment in mice.

Pain promotes protective behavior but can interfere with other biologically important goals. Survival may require overcoming pain to obtain rewards, secure resources or escape danger, yet evidence for pain modulation by competing demands and endogenous modulatory systems during goal pursuit is lacking. We developed a paradigm in which participants chose whether to pursue monetary rewards despite painful heat stimulation during fMRI, under placebo or opioid receptor blockade with naloxone. Actively pursuing motivational goals during painful stimulation reduced perceived pain and increased fMRI signal in pain-modulatory cortical regions, including multiple subregions of the rostral anterior cingulate cortex (rACC) and dorsolateral prefrontal cortex, alongside enhanced rACC-periaqueductal gray coupling, consistent with recruitment of the descending pain modulatory system. Behavioral and neural effects were attenuated by naloxone, supporting a mediating role for endogenous opioids. These findings provide convergent evidence that active goal pursuit engages opioidergic pain modulatory mechanisms to reduce pain in humans.

Patients with bowel disease can develop referred somatic pain at a later time with unknown molecular mechanisms. Using experimental mice with colitis induced by intracolonic installation of 2,4,6-Trinitrobenzenesulfonic acid (TNBS), we find an increase in the percentage of hind paw primary afferent neurons expressing Piezo2 or calcitonin gene-related peptide (CGRP), which are attenuated by TrkB.T1 knockout (KO). Concomitantly, TrkB.T1 KO also attenuates colitis-induced hind paw mechanical hypersensitivity and pain. Next, we find that TrkB.T1 is expressed in spinal cord astrocytes and its expression level is increased by colitis. TrkB.T1 KO reduces colitis-induced upregulation of Tumor necrosis factor-alpha (TNF-) mRNA but not upregulation of interleukin (IL)-6 mRNA in the spinal cord. Using calcium (Ca2+) imaging and ex vivo approaches, we find that TNF- elicits Ca2+ transients in capsaicin-sensitive as well as capsaicin-insensitive DRG neurons, and increases Piezo2 and CGRP expression in DRG neurons via distinct signaling pathways. Notably, TNF-or colitis-induced Piezo2 upregulation in L4 DRG neurons is mediated by or associated with the PI3K/Akt pathway that does not participate in CGRP upregulation. In contrast, CGRP upregulation in hind paw primary afferent neurons is associated with an upregulation of phosphorylated cAMP response element binding protein (p-CREB). Finally, we find that TrkB.T1 KO does not change the expression level of transient receptor potential cation channel subfamily V member 1 (TrpV1) in L4 DRG in colitis, explaining the ineffectiveness of TrkB.T1 KO on colitis-induced hind paw thermal hyperalgesia. These results suggest complex and distinct molecular pathways in colitis-induced somatic pain modalities and provide information for specific pain modality management.

Validated measures of pain catastrophizing primarily assess catastrophizing as a stable trait. However, emerging evidence suggests catastrophizing fluctuates with context, highlighting a need for ecologically valid methods to capture it. This study evaluated large language models (LLMs) as implicit markers of catastrophizing from free text responses from ninety-one adults with chronic pain receiving long-term opioid therapy (57.3 percent Female; mean age = 60.5 years). Patients completed baseline measures, including the trait pain catastrophizing scale (PCS), followed by a 10 minute writing task after random assignment to a negative, positive, or neutral pain-coping condition. State affect and pain were assessed before and after writing tasks and again after a cold pressor task (4 degrees C; <= 2 minutes). A state PCS followed the cold pressor task. Free text responses were analyzed using four LLMs (Claude Opus 4; GPT Mini 4o; Llama 4 Maverick; and Gemini 2.5 Pro). ANOVA based results supported discriminant validity, as all four LLM-derived pain catastrophizing scores differentiated negative from positive and neutral pain-coping conditions. Convergent validity was model dependent; only Gemini derived scores correlated with state catastrophizing (r = .22) and pain unpleasantness (r = .23). Divergent validity was mixed. LLM derived scores were unrelated to pain intensity, but Gemini and Claude derived scores showed small correlations with trait PCS (rs = .21; 28, respectively). All LLM-derived scores also correlated with negative affect (rs range = .29 - .41), comparable in magnitude to state PCS, suggesting limited specificity. These findings provide preliminary evidence that certain LLMs may serve as implicit markers of state pain catastrophizing, but further study is needed.

The spinal dorsal horn is the primary processing site of nociceptive sensory input from the periphery. Excitatory spinal interneurons releasing glutamate can amplify this information before it is sent to the brain, whereas inhibitory neurons releasing GABA and/or glycine can suppress the outflow of nociceptive signals. An imbalance favoring excitation is thought to underlie certain aspects of chronic pain. Although rodent studies have identified spinal mechanisms underlying hyperalgesia and allodynia, little is known about the anatomical changes associated with chronic pain in the human spinal cord, a gap in knowledge we sought to address in this study. Using immunohistochemistry and in situ hybridization on lumbar spinal cord tissue recovered from organ donors, we characterized neuronal size and density across the human dorsal horn and confirmed the presence of the human equivalent of the lateral spinal nucleus in many individuals. Chronic lower limb pain was not associated with changes in neuronal density in the dorsal horn. Likewise, the ratio of excitatory (SLC17A6+) to inhibitory (PAX2+) neurons remained consistent across laminae for age, sex and chronic pain state, providing no evidence for selective loss of inhibitory neurons with chronic pain in humans. We found no differences in the size or density of the postsynaptic markers Homer1 and gephyrin between groups, suggesting glutamatergic and GABAergic postsynaptic sites remain structurally stable. These findings provide a thorough evaluation of cellular anatomy of the human dorsal horn and form a foundation for future studies investigating neuronal changes that may contribute to chronic pain in humans.

Background: Fluctuations in pain intensity are intrinsic to non-specific chronic low back pain (nsCLBP). Nevertheless, pain fluctuations have rarely been considered when investigating pathophysiological mechanisms. Therefore, a novel study protocol was developed and implemented to systematically assess the impact of fluctuating pain states on pain-related measures. Methods: The final study cohort consisted of 45 nsCLBP patients and 47 age- and sex-matched healthy controls (HCs). Patients participated in three visits, conducted during different pain states (i.e. clinically relevant pain, low-intensity clinical pain / pain-free, clinically irrelevant pain induced using a Qutenza 8% capsaicin patch). Pain fluctuations were monitored through online assessments every four days and guided the pseudorandomized visit scheduling. HCs participated in a single visit. Each study visit comprised a multimodal battery of pain-related measures. Results: 93.33% of patients completed all three visit types in a pseudorandomized order (chi-squared=1.50, p=0.826). Visit scheduling was possible due to the high self-report adherence (median=93.48%), unrelated to self-report burden (rho=-0.097, p=0.53). Study visits were conducted during different pain states, as indicated by: i) the significantly higher low back pain intensity in the clinically relevant pain visit (mean[SD]: 3.98[0.90]), compared to the low-intensity clinical pain (1.03[0.86]) and clinically irrelevant pain (1.13[0.82]) visits (p-values<0.001), as well as by ii) the successful induction of a moderate-to-high clinically irrelevant pain across assessments. Conclusion: Despite scheduling complexity and pain state transition uncertainty, a pain state-dependent pseudorandomized study design is feasible and could improve the understanding of nsCLBP mechanisms.

While progress has been made in identifying pain biomarkers using neuroimaging, the development of reliable EEG-based biomarkers remains challenging, limited by small sample sizes and the lack of adequate control conditions. We present a comprehensive dataset from 125 pain-free adults, comprising electroencephalogram (EEG) recordings, and behavioural, sociodemographic, and psychological data. Galvanic skin response and electrocardiogram data were also recorded in a subset of participants (n = 76). Participants received two sustained painful stimulations (thermal, chemical) and two sustained aversive non-painful stimulations (auditory, taste), each delivered twice (with and without continuous intensity ratings). Data are provided in Brain Imaging Data Structure format, where all physiological, stimulus-related, and behavioural data are synchronized within the EEG data files for easy access and analysis. Technical validation confirmed data integrity, with spectral and physiological analyses showing responses associated with stimulus intensity and subjective pain/unpleasantness levels. By providing multimodal physiological data across painful and non-painful aversive conditions, this initiative represents a valuable resource for developing or validating biomarkers and exploring the multidimensional nature of pain perception.